Serotonin News and Research

Latest Serotonin News and Research

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

T. gondii can cause inflammation in the brain

A parasite thought to be harmless and found in many people may actually be causing subtle changes in the brain, leading to suicide attempts.

17 Aug 2012

Cortisol levels increased in youth at high risk for psychosis

Untreated young people at clinical high risk for psychosis have increased salivary cortisol levels compared with treated high-risk patients and mentally healthy individuals, study results show.

16 Aug 2012

Cortisol levels increased in youth at high risk for psychosis

Untreated young people at clinical high risk for psychosis have increased salivary cortisol levels compared with treated high-risk patients and mentally healthy individuals, study results show.

15 Aug 2012

TG2 plays a key role in serotonin deficiency associated with depression

Connecting the dots between two molecules whose levels are decreased in depression and increased by current antidepressants could yield new therapies, researchers say.

15 Aug 2012

Creatine may fight major depression in women

Women battling stubborn major depression may have a surprising new ally in their fight—the muscle-building dietary supplement creatine.

7 Aug 2012

Exercise partially alleviates depression in heart failure patients

Structured exercise achieves modest reductions in depressive symptoms relative to usual care among patients with heart failure the results of a randomized-controlled trial show.

6 Aug 2012

Exercise improves mood in heart failure patients

Structured exercise achieves modest reductions in depressive symptoms relative to usual care among patients with heart failure, the results of a randomized-controlled trial show.

6 Aug 2012

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

Novel way to monitor real-time chemical changes in brains of patients undergoing DBS

Mayo Clinic researchers have found a novel way to monitor real-time chemical changes in the brains of patients undergoing deep brain stimulation (DBS). The groundbreaking insight will help physicians more effectively use DBS to treat brain disorders such as Parkinson's disease, depression and Tourette syndrome.

16 Jul 2012

Pressure Point develops 72 hour low-cost dermal device to effectively reduce PONV

Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.

12 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

Adiponectin reduces depression-like symptoms in mice

A hormone with anti-diabetic properties also reduces depression-like symptoms in mice, researchers from the School of Medicine at the UT Health Science Center San Antonio reported today.

10 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

Rapamycin enhances learning and memory in young mice

Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with a drug that has Polynesian roots.

30 Jun 2012

Scientists successfully tag serotonin transporter to track movements of single molecules

In a process akin to belling an infinitesimal cat, scientists have managed to tag a protein that regulates the neurotransmitter serotonin with tiny fluorescent beads, allowing them to track the movements of single molecules for the first time.

29 Jun 2012